Skip to content

DMT research published in 2024

Page 3 of 3: studies 41 to 60 of 60, newest first. Back to the DMT overview

Studies

Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties

Molecular Psychiatry March 14, 2024 Pol Puigseslloses, Gabriel Ketsela, Nicola Weiss et al. 23 citations

Abstract Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to...

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

European Neuropsychopharmacology March 1, 2024 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B Silva et al. 25 citations

Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at...

DOI: 10.1016/j.euroneuro.2023.12.006 (opens in new tab) Full text (opens in new tab) Entheogens Clinical trial Dose-response study Mood disorders +6

Unlocking the biosynthesis of psychedelic-inspired indolethylamines.

Trends in biochemical sciences March 1, 2024 Abhishek K. Sen, J. Andrew Jones 2 citations

A recent report by Chen et al. describes the discovery of RmNMT, a highly active and promiscuous tryptamine N-methyltransferase from the cane toad, Rhinella marina. N,N-dimethyltryptamine derivatives produced by this enzyme were then evaluated for their potential to serve as next-generation treatments for mental health disorders.

DOI: 10.1016/j.tibs.2023.12.009 (opens in new tab) Full text (opens in new tab) N-dimethyltryptamine N-methylation Psychedelic indolethylamine Serotonin receptor binding +4

The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness

Psychoactives February 26, 2024 Frankie A. Colosimo, Philip Borsellino, Reese I. Krider et al. 8 citations

The human brain is an extraordinarily complex organ responsible for all aspects of cognition and control. Billions of neurons form connections with thousands of other neurons, resulting in trillions of synapses that create a vast and intricate network. This network is subjected to continuous remodeling that adapts to environmental and developmental changes. The resulting neuroplasticity is...

Defining 5-MeO-DMT in Historical and Cultural Contexts

World Futures February 17, 2024 Azul Delgrasso 4 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic and entheogenic compound that has been used for centuries by Indigenous Peoples in the Amazon, Caribbean, and more recently in communities in Northern Mexico in ceremonial practices and to connect with nature. In recent years, there has been growing interest in 5-MeO-DMT to treat mental health conditions such as depression, anxiety...

DOI: 10.1080/02604027.2024.2330255 (opens in new tab) Radical photochemical reactions Alkaloids

Emotion regulation effects of Ayahuasca in experienced subjects during implicit aversive stimulation: An fMRI study.

Journal of Ethnopharmacology February 10, 2024 Tiago Arruda Sanchez, Lucas Rego Ramos, Felipe Araujo et al. 12 citations

Ayahuasca is a beverage used in Amazonian traditional medicine and it has been part of the human experience for millennia as well as other different psychoactive plants. Although Ayahuasca has been proposed as potentially therapeutic as an anxiolytic and antidepressant, whilst no studies have been carried out so far investigating their direct effect on brain emotional processing. This study...

Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.

ACS Medicinal Chemistry Letters February 8, 2024 Navoda Jayakodiarachchi, Mallory A Maurer, Daniel C Schultz et al. 6 citations

Herein, we report the synthesis and characterization of a novel set of substituted indazole-ethanamines and indazole-tetrahydropyridines as potent serotonin receptor subtype 2 (5-HT2) agonists. Specifically, we examine the 5-HT2 pharmacology of the direct indazole analogs of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and related serotonergic tryptamines, and highlight the need for rigorous...

DOI: 10.1021/acsmedchemlett.3c00566 (opens in new tab) Full text (opens in new tab) Drug development Serotonin receptors Medicinal chemistry Pharmacology

Effects of DMT on mental health outcomes in healthy volunteers

Scientific Reports February 7, 2024 Christopher Timmermann, Richard J. Zeifman, David Erritzøe et al. 37 citations

Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness limitations. Here, we explored the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT), a closely related, but faster-acting...

DOI: 10.1038/s41598-024-53363-y (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment DMT Research Clinical trials +1

Transient destabilization of whole brain dynamics induced by DMT

bioRxiv January 29, 2024 Juan Ignacio Piccinini, Yonatan Sanz Perl, Carla Pallavicini et al. preprint

Abstract The transition towards the brain state induced by psychedelic drugs is frequently neglected in favor of a static description of their acute effects. We used a time-dependent whole-brain model to reproduce large-scale brain dynamics measured with fMRI from 15 volunteers under 20 mg intravenous N,N-Dimethyltryptamine (DMT), a short-acting psychedelic. To capture its transient effects, we...

On the advances in machine learning and complex network measures to an EEG dataset from DMT experiments

Journal of Physics: Complexity January 22, 2024 Caroline L. Alves, Manuel Ciba, Thaise G. L. de O. Toutain et al. 5 citations

There is a growing interest in the medical use of psychedelic substances, as preliminary studies using them for psychiatric disorders have shown positive results. In particular, one of these substances is N, N-dimethyltryptamine (DMT), an agonist serotonergic psychedelic that can induce profound alterations in the state of consciousness. In this work, we use an exploratory tool to reveal...

Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process Theory.

Neuroscience Letters January 18, 2024 Hector Vargas-Perez, Fernando Minauro-Sanmiguel, Ryan Ting-A-Kee et al. 2 citations

According to the opponent-process theory of drug addiction, the intake of an addictive substance initiates two processes: a rapid primary process that results in the drug's rewarding effects, and a slower opponent process that leads to the aversive motivational state of drug aftereffects. This aversive state is integral in the desire, pursuit, and maintenance of drug use, potentially leading to...

DOI: 10.1016/j.neulet.2023.137597 (opens in new tab) Full text (opens in new tab) Psychedelics Addiction research Drug effects Behavioral studies

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

medRxiv January 4, 2024 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 5 citations preprint

Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...

Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.

Journal of Psychoactive Drugs 2024 Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al. 4 citations

In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...

N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q).

Journal of Psychoactive Drugs 2024 David Wyndham Lawrence, Alex P DiBattista, Christopher Timmermann 3 citations

This study investigated the sense of familiarity attributed to N, N-dimethyltryptamine (DMT) experiences. 227 naturalistic inhaled-DMT experiences reporting a sense of familiarity were included. No experiences referenced a previous DMT or psychedelic experience as the source of the familiarity. A high prevalence of concomitant features discordant from ordinary consciousness were identified:...

Psychological and physiological effects of extended DMT.

Journal of Psychopharmacology 2024 Lisa Luan, Emma Eckernäs, Michael Ashton et al. 41 citations

N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its potential role in treating mental health conditions. In a within-subjects,...

Psilocybin and Other Classic Psychedelics in Depression.

Current Topics in Behavioral Neurosciences 2024 D J Nutt, Joseph Peill, B Weiss et al. 30 citations

Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target the 5-HT2A receptor such as psilocybin and DMT. These produce plasma-concentration related psychological effects such as hallucinations and out of body experiences,...

Shared functional connectome fingerprints following ritualistic ayahuasca intake.

Neuroimage 2024 Pablo Mallaroni, Natasha L. Mason, Lilian Kloft et al. 17 citations

The knowledge that brain functional connectomes are unique and reliable has enabled behaviourally relevant inferences at a subject level. However, whether such "fingerprints" persist under altered states of consciousness is unknown. Ayahuasca is a potent serotonergic psychedelic which produces a widespread dysregulation of functional connectivity. Used communally in religious ceremonies, its...

DOI: 10.1016/j.neuroimage.2023.120480 (opens in new tab) Full text (opens in new tab) DMT Entheogens Brain connectivity connectome Neuroimaging FMRI +8

Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review.

International journal of toxicology 2024 Eleanor White, Tom Kennedy, Simon Ruffell et al. 13 citations

The objective of this paper is to conduct a systematic thematic review of adverse events, safety, and toxicity of traditional ayahuasca plant preparations and its main psychoactive alkaloids (dimethyltryptamine [DMT], harmine, harmaline, and tetrahydroharmine), including discussing clinical considerations (within clinical trials or approved settings). A systematic literature search of...

DOI: 10.1177/10915818241230916 (opens in new tab) Full text (opens in new tab) Adverse events Hallucinogens Ayahuasca safety: ayahuasca Good safety profile +6

Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.

Frontiers in Psychiatry 2024 Aleksander Kwaśny, Alina Wilkowska, Wiesław Jerzy Cubała 10 citations

Psychedelic agents have regained the attention of pharmaceutical companies as promising treatments for depressive episodes. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), an atypical psychedelic, is emerging as a potentially effective, novel rapid-acting antidepressant. In this systematic review, we analyze the safety and tolerability evidence from clinical trials. Following the Preferred...

DOI: 10.3389/fpsyt.2024.1477996 (opens in new tab) Full text (opens in new tab) 5-MEO-DMT Psychedelics entheogens Hallucinogens Tolerability +6

Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT).

Frontiers in Pharmacology 2024 Carla Soares, Gisela Lima, Marta Lapo Pais et al. 13 citations

The modulation of social cognition is suggested as a possible mechanism contributing to the potential clinical efficacy of psychedelics in disorders involving socio-emotional and reward processing deficits. Resting-state functional Magnetic Resonance Imaging (rs-fMRI) can be used to detect changes in brain connectivity during psychedelic-induced states. Thus, this pharmacoimaging study...

DOI: 10.3389/fphar.2024.1454628 (opens in new tab) Full text (opens in new tab) Neuroscience brain science Neural studies Neurology Social understanding +10